Building on their previous research into SARS-CoV, researchers have identified a human monoclonal antibody capable of preventing both SARS-CoV and SARS-CoV-2 from infecting cultured cells. This cross-neutralizing feature could potentially mitigate future related coronaviruses.
A novel study conducted by researchers at Harvard Medical School (MA, USA) has identified how the maternal gut microbiome could protect their newborn children from E. coli infection.
Using animal models, researchers have discovered that antibodies can be coaxed into proliferating and targeting HIV.
New study determines a neutralizing antibody which binds to the most pandemic strain of norovirus in humans that could be utilized for an effective vaccine.
Researchers have successfully used monoclonal antibodies to protect animal models from Candida infections for the first time, demonstrating their potential for treating this fungal disease.
Collaborative research efforts with scientists from Janssen, the Scripps Research Institute, the University of Hong Kong, the University of Pennsylvania and more has led to success in creating a promising novel long-lasting llama-derived antibody therapy for influenza.
A pioneering treatment, an antibody termed PRN100, is to be given to a patient with sporadic Creutzfeldt-Jakob disease for the first time.
A recent study carried out by researchers from the University of Zurich and University Hospital Zurich has discovered that the production of broad acting antibodies is dependent on the genome of the virus.
Small-molecule compounds designed to tag the cell surface of Gram-negative bacteria and trigger an immunological response have shown promise.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
